1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. CureVac N.V.
  6. News
  7. Summary
    CVAC   NL0015436031

CUREVAC N.V.

(CVAC)
  Report
Delayed Nasdaq  -  04:00 2022-08-12 pm EDT
13.48 USD   +0.67%
07/27BioNTech, Pfizer Challenge CureVac's COVID-19 Vaccine Patent Infringement Case In US
MT
07/26BioNTech, Pfizer sue CureVac in U.S. over COVID-19 vaccine patent claims
RE
07/06MARKETSCREENER'S WORLD PRESS REVIEW : July 6, 2022
MS
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

CureVac Sues BioNTech in Germany for Infringement of mRNA-Related Patents

07/05/2022 | 08:06am EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
BIONTECH SE 1.11% 160.35 Delayed Quote.-37.80%
CUREVAC N.V. 0.67% 13.48 Delayed Quote.-60.71%
PFIZER, INC. 3.77% 50.11 Delayed Quote.-15.14%
All news about CUREVAC N.V.
07/27BioNTech, Pfizer Challenge CureVac's COVID-19 Vaccine Patent Infringement Case In US
MT
07/26BioNTech, Pfizer sue CureVac in U.S. over COVID-19 vaccine patent claims
RE
07/06MARKETSCREENER'S WORLD PRESS REVIEW : July 6, 2022
MS
07/05CUREVAC N : Files Patent Infringement Lawsuit in Germany Against BioNTech - Form 6-K
PU
07/05BioNTech Says Will 'Vigorously' Defend Patent Infringement Allegations
MT
07/05BioNTech Says 'Work is Original' Amid CureVac Lawsuit On mRNA-Related Patents Infringem..
MT
07/05SECTOR UPDATE : Health Care Stocks Decline Premarket Tuesday
MT
07/05CureVac Sues BioNTech in Germany for Infringement of mRNA-Related Patents
MT
07/05CureVac Sues BioNTech for Alleged Infringement of Some COVID-19 Vaccine Patents
MT
07/05CureVac Files Patent Infringement Lawsuit in Germany Against BioNTech
EQ
More news
Analyst Recommendations on CUREVAC N.V.
More recommendations
Financials
Sales 2022 80,4 M 82,4 M 82,4 M
Net income 2022 -199 M -204 M -204 M
Net cash 2022 507 M 520 M 520 M
P/E ratio 2022 -12,3x
Yield 2022 -
Capitalization 2 459 M 2 521 M 2 521 M
EV / Sales 2022 24,3x
EV / Sales 2023 15,0x
Nbr of Employees 824
Free-Float 47,5%
Chart CUREVAC N.V.
Duration : Period :
CureVac N.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CUREVAC N.V.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 7
Last Close Price 13,15 €
Average target price 25,31 €
Spread / Average Target 92,5%
EPS Revisions
Managers and Directors
Franz-Werner Haas Chief Executive Officer
Pierre Kemula Chief Financial Officer & Managing Director
Baron Jean Stéphenne Chairman-Supervisory Board
Igor Splawski Chief Scientific Officer
Malte Greune Chief Operating & Production Officer
Sector and Competitors
1st jan.Capi. (M$)
CUREVAC N.V.-60.71%2 504
MODERNA, INC.-32.35%67 212
LONZA GROUP AG-23.32%46 073
IQVIA HOLDINGS INC.-14.23%45 135
SEAGEN INC.12.57%32 099
ALNYLAM PHARMACEUTICALS, INC.35.27%27 533